TD-1211

DRUG5 trials

Sponsors

Glycyx Therapeutics

Conditions

HealthyOpioid Induced ConstipationOpioid-induced ConstipationOpioid-induced Constipation (OIC)

Phase 1

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

CompletedNCT01040637

Glycyx TherapeuticsHealthy, Opioid-induced Constipation

Start: 2010-01-01End: 2010-10-01Updated: 2026-05-22

A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

CompletedNCT01568411

Glycyx TherapeuticsHealthy

Start: 2012-04-01End: 2012-06-01Updated: 2026-05-22

Phase 2

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

CompletedNCT01333540

Glycyx TherapeuticsOpioid-induced Constipation (OIC)

Start: 2011-05-01End: 2012-06-01Updated: 2026-05-22

A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

CompletedNCT01401985

Glycyx TherapeuticsOpioid Induced Constipation

Start: 2011-10-01End: 2012-08-01Updated: 2026-05-22

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

CompletedNCT01459926

Glycyx TherapeuticsOpioid Induced Constipation

Start: 2011-11-01End: 2012-06-01Updated: 2026-05-22